Psoriasis: emerging therapeutic strategies (Q36028220)

11 August 2017

1 reference

title

Psoriasis: emerging therapeutic strategies (English)

1 reference

11 August 2017

Alice B Gottlieb

1

1 reference

11 August 2017

1 January 2005

1 reference

Nature Reviews Drug Discovery

11 August 2017

1 reference

11 August 2017

4

1 reference

11 August 2017

19-34

1 reference

11 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd1607

11 August 2017

0 references

cites work

Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances

1 reference

Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array

21 January 2018

1 reference

A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis

21 January 2018

1 reference

Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques

21 January 2018

1 reference

Recombinantly engineered human proteins: transforming the treatment of psoriasis

21 January 2018

1 reference

The immunologic basis for the treatment of psoriasis with new biologic agents

21 January 2018

1 reference

Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha

21 January 2018

1 reference

Adhesion receptors of the immune system

21 January 2018

1 reference

TH1 and TH2 lymphocyte development and regulation of TH cell-mediated immune responses of the skin

21 January 2018

1 reference

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

21 January 2018

1 reference

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

21 January 2018

1 reference

Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

21 January 2018

1 reference

Role of the CD28 receptor in T-cell activation

21 January 2018

1 reference

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

21 January 2018

1 reference

Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.

21 January 2018

1 reference

Connections between psoriasis and Crohn's disease

21 January 2018

1 reference

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis

21 January 2018

1 reference

A randomized trial of etanercept as monotherapy for psoriasis.

21 January 2018

1 reference

Keratinocyte growth regulation by the products of immune cells

21 January 2018

1 reference

Cytokines: IL-20 - a new effector in skin inflammation

21 January 2018

1 reference

Significance and pathogenesis of basal keratinocyte herniations in psoriasis

21 January 2018

1 reference

The dermoepidermal junction in psoriatic skin as revealed by scanning electron microscopy.

21 January 2018

1 reference

Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated immunophenotype. Implications for carcinogenesis.

21 January 2018

1 reference

E-selectin and vascular cell adhesion molecule-1 are critical for initial trafficking of helper-inducer/memory T cells in psoriatic plaques.

21 January 2018

1 reference

Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.

21 January 2018

1 reference

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

21 January 2018

1 reference

CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study

21 January 2018

1 reference

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

21 January 2018

1 reference

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis

21 January 2018

1 reference

Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

21 January 2018

1 reference

Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis

21 January 2018

1 reference

The immunologic and genetic basis of psoriasis

21 January 2018

1 reference

Clinical research helps elucidate the role of tumor necrosis factor-αin the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes

21 January 2018

1 reference

A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis

21 January 2018

1 reference

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

21 January 2018

1 reference

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

21 January 2018

1 reference

Adverse reactions to TNF-α inhibitors in rheumatoid arthritis

21 January 2018

1 reference

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

Infections and anti–tumor necrosis factor α therapy

21 January 2018

1 reference

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

21 January 2018

1 reference

Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells

21 January 2018

1 reference

Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells

21 January 2018

1 reference

Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization

21 January 2018

1 reference

The roles of interleukin-18 in collagen-induced arthritis in the BB rat.

21 January 2018

1 reference

Maintaining the norm: T-cell homeostasis

21 January 2018

1 reference

Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis?

21 January 2018

1 reference

The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders

21 January 2018

1 reference

Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells

21 January 2018

1 reference

Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation

21 January 2018

1 reference

Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn's disease: in the shadow of infliximab?

21 January 2018

1 reference

Natalizumab for active Crohn's disease

21 January 2018

1 reference

Role of interferon-gamma in cutaneous trafficking of lymphocytes with emphasis on molecular and cellular adhesion events

21 January 2018

1 reference

Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis

21 January 2018

1 reference

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

21 January 2018

1 reference

Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques

21 January 2018

1 reference

Immunologic mechanisms in psoriasis

21 January 2018

1 reference

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

21 January 2018

1 reference

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis

21 January 2018

1 reference

Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines

21 January 2018

1 reference

Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner

21 January 2018

1 reference

Inhibition of dendritic cell differentiation by fumaric acid esters

21 January 2018

1 reference

The Stat family in cytokine signaling

21 January 2018

1 reference

Targeting JNK for therapeutic benefit: from junk to gold?

21 January 2018

1 reference

The IKK NF-kappa B system: a treasure trove for drug development

21 January 2018

1 reference

Assessment of patients with psoriatic arthritis: a review of currently available measures

21 January 2018

1 reference

PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy

21 January 2018

1 reference

CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry.

21 January 2018

1 reference

Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells

21 January 2018

1 reference

Climatotherapy at the Dead Sea is a remittive therapy for psoriasis: combined effects on epidermal and immunologic activation

21 January 2018

1 reference

Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis.

21 January 2018

1 reference

Lymphocyte trafficking in psoriasis: a new perspective emphasizing the dermal dendrocyte with active dermal recruitment mediated via endothelial cells followed by intra-epidermal T-cell activation

21 January 2018

1 reference

Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes

21 January 2018

1 reference

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis

21 January 2018

1 reference

Psoriasis causes as much disability as other major medical diseases

31 March 2020

1 reference

Quality of life in patients with psoriasis: a systematic literature review

31 March 2020

1 reference

Diagnosis and management of psoriatic arthritis

31 March 2020

1 reference

Natural history of psoriasis in 61 twin pairs

31 March 2020

1 reference

Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial

31 March 2020

1 reference

The pathomechanisms of psoriasis; the skin immune system and cyclosporin

31 March 2020

1 reference

Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation

31 March 2020

1 reference

Epidermal T lymphocytes and HLA-DR expression in psoriasis

31 March 2020

1 reference

Dermal injection of immunocytes induces psoriasis

31 March 2020

1 reference

T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice

31 March 2020

1 reference

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

31 March 2020

1 reference

Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study

31 March 2020

1 reference

Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4

31 March 2020

1 reference

Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis

31 March 2020

1 reference

Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment

31 March 2020

1 reference

31 March 2020

1 reference

Use of cyclosporin in psoriasis

31 March 2020

1 reference

Estrogens and human scalp hair growth-still more questions than answers

31 March 2020

1 reference

The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system

31 March 2020

1 reference

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

31 March 2020

1 reference

Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody

31 March 2020

1 reference

Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris

31 March 2020

1 reference

Decreased growth inhibition by recombinant gamma interferon is associated with increased transforming growth factor-alpha production in keratinocytes cultured from psoriatic lesions

31 March 2020

1 reference

Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes

31 March 2020

1 reference

GM-CSF activates regenerative epidermal growth and stimulates keratinocyte proliferation in human skin in vivo

31 March 2020

1 reference

Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol.

31 March 2020

1 reference

Changes in keratinocyte maturation during wound healing

31 March 2020

1 reference

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

31 March 2020

1 reference

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

31 March 2020

1 reference

The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody

31 March 2020

1 reference

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

31 March 2020

1 reference

Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions

31 March 2020

1 reference

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

31 March 2020

1 reference

Inflammatory infiltrate and interleukin-8 expression in the synovium of psoriatic arthritis--an immunohistochemical and mRNA analysis

31 March 2020

1 reference

Immunohistochemical markers for arthritis in psoriasis

31 March 2020

1 reference

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

31 March 2020

1 reference

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

31 March 2020

1 reference

Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions

31 March 2020

1 reference

Power Doppler sonography: improving disease activity assessment in inflammatory musculoskeletal disease

31 March 2020

1 reference

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

31 March 2020

1 reference

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

31 March 2020

1 reference

Etanercept as monotherapy in patients with psoriasis

31 March 2020

1 reference

In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered.

31 March 2020

1 reference

A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis

31 March 2020

1 reference

Interleukin-18: A novel cytokine in inflammatory rheumatic disease

31 March 2020

1 reference

Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production

31 March 2020

1 reference

Immune and inflammatory processes in cutaneous tissues. Mechanisms and speculations

31 March 2020

1 reference

Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin

31 March 2020

1 reference

Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor

31 March 2020

1 reference

Intercellular adhesion molecule-I (ICAM-I) expression correlated to inflammation

31 March 2020

1 reference

Immunohistochemical studies of infiltrating cells in early and chronic lesions of psoriasis

31 March 2020

1 reference

Role of integrin alphaE(CD103)beta7 for tissue-specific epidermal localization of CD8+ T lymphocytes

31 March 2020

1 reference

Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes

31 March 2020

1 reference

Evidence for vascular endothelial growth factor (VEGF) as a modifier gene in psoriasis

31 March 2020

1 reference

Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset.

31 March 2020

1 reference

In situ localization of interferons in psoriatic lesions

31 March 2020

1 reference

Thalidomide: A review of approved and investigational uses

31 March 2020

1 reference

IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach

31 March 2020

1 reference

Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis

31 March 2020

1 reference

Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients

31 March 2020

1 reference

Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis

31 March 2020

1 reference

Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study

31 March 2020

1 reference

The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network

31 March 2020

1 reference

Dimethylfumarate is a potent inducer of apoptosis in human T cells

31 March 2020

1 reference

Treatment Of Psoriasis With Oral Mycophenolic Acid

31 March 2020

1 reference

Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infilitration in psoriatic plaques by topical calcitriol

31 March 2020

1 reference

Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes

31 March 2020

1 reference

Effectiveness of psoriatic arthritis therapies

31 March 2020

1 reference

Soluble IL-2 receptor and CD25 cells in psoriasis: effects of cyclosporin A and PUVA therapy

31 March 2020

1 reference

Immunologic targets in psoriasis

31 March 2020

1 reference

The C-X-C chemokine Mig is highly expressed in the papillae of psoriatic lesions

31 March 2020

1 reference

Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells

31 March 2020

1 reference

A subset of macrophages located along the basement membrane ("lining cells") is a characteristic histopathological feature of psoriasis

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Severe Psoriasis – Oral Therapy with a New Retinoid

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD1607

1 reference

PubMed ID

15688070

Dimensions Publication ID

11 August 2017

0 references

1 reference

PubMed ID

15688070